Influences of social uncertainty and serotonin on gambling decisions.

Gabriele Bellucci, Thomas F Münte, Soyoung Q Park
Author Information
  1. Gabriele Bellucci: Department of Computational Neuroscience, Max Planck Institute for Biological Cybernetics, 72076, Tübingen, Germany. gabriele.a.bellucci@gmail.com.
  2. Thomas F Münte: Department of Neurology, Universitätsklinikum Schleswig-Holstein, Lübeck, Germany.
  3. Soyoung Q Park: Department of Psychology I, University of Lübeck, Lübeck, Germany. soyoung.q.park@gmail.com.

Abstract

In many instances in life, our decisions' outcomes hinge on someone else's choices (i.e., under social uncertainty). Behavioral and pharmacological work has previously focused on different types of uncertainty, such as risk and ambiguity, but not so much on risk behaviors under social uncertainty. Here, in two different studies using a double-blind, placebo-controlled, within-subject design, we administrated citalopram (a selective-serotonin-reuptake inhibitor) to male participants and investigated decisions in a gambling task under social and nonsocial uncertainty. In the social condition, gamble outcomes were determined by another participant. In the nonsocial condition, gamble outcomes were determined by a coin toss. We observed increased gamble acceptance under social uncertainty, especially for gambles with lower gains and higher losses, which might be indicative of a positivity bias in social expectations in conditions of high uncertainty about others' behaviors. A similar effect was found for citalopram, which increased overall acceptance behavior for gambles irrespective of the source of uncertainty (social/nonsocial). These results provide insights into the cognitive and neurochemical processes underlying decisions under social uncertainty, with implications for research in risk-taking behaviors in healthy and clinical populations.

References

  1. Cogn Affect Behav Neurosci. 2018 Feb;18(1):127-142 [PMID: 29318509]
  2. Psychol Rev. 2020 Mar;127(2):245-280 [PMID: 31750686]
  3. J Stud Alcohol Suppl. 2002 Mar;(14):164-72 [PMID: 12022722]
  4. J Exp Psychol Gen. 2014 Dec;143(6):2074-81 [PMID: 25347535]
  5. Perspect Psychol Sci. 2015 Nov;10(6):772-89 [PMID: 26581735]
  6. Science. 2007 Jan 26;315(5811):515-8 [PMID: 17255512]
  7. Trends Cogn Sci. 2008 Jan;12(1):31-40 [PMID: 18069045]
  8. Dev Psychol. 2005 Jul;41(4):625-35 [PMID: 16060809]
  9. J Affect Disord. 2006 Oct;95(1-3):119-23 [PMID: 16782204]
  10. Curr Dir Psychol Sci. 2013 Apr;22(2):114-120 [PMID: 25544805]
  11. Neuropsychopharmacology. 2011 Jan;36(2):402-10 [PMID: 20980990]
  12. Hum Brain Mapp. 2017 Mar;38(3):1233-1248 [PMID: 27859899]
  13. Eur Neuropsychopharmacol. 2013 Aug;23(8):919-30 [PMID: 23051938]
  14. Psychopharmacology (Berl). 2002 Jan;159(2):216-21 [PMID: 11862352]
  15. Cogn Psychol. 2010 Sep;61(2):87-105 [PMID: 20553763]
  16. Elife. 2021 Jan 11;10: [PMID: 33427198]
  17. Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7007-7012 [PMID: 28630324]
  18. Dev Sci. 2011 Mar;14(2):F1-10 [PMID: 21499511]
  19. Soc Cogn Affect Neurosci. 2014 Sep;9(9):1419-25 [PMID: 23996287]
  20. J Exp Psychol Gen. 2020 Aug;149(8):1567-1586 [PMID: 31916837]
  21. Nat Neurosci. 2008 Apr;11(4):398-403 [PMID: 18368046]
  22. PLoS One. 2011 Mar 14;6(3):e17725 [PMID: 21423732]
  23. Nat Hum Behav. 2020 Jun;4(6):646-655 [PMID: 32514040]
  24. Neuropsychopharmacology. 2003 Jan;28(1):153-62 [PMID: 12496952]
  25. Neurosci Biobehav Rev. 2018 Sep;92:378-389 [PMID: 29958872]
  26. Cognition. 2008 Sep;108(3):796-803 [PMID: 18721917]
  27. Br J Psychol. 2017 May;108(2):276-295 [PMID: 26990740]
  28. Nat Hum Behav. 2019 May;3(5):426-435 [PMID: 31011164]
  29. J Cogn Neurosci. 2009 Sep;21(9):1709-19 [PMID: 18823228]
  30. J Exp Psychol Gen. 2015 Feb;144(1):12-7 [PMID: 25485604]
  31. Soc Cogn Affect Neurosci. 2018 Jan 1;13(1):52-62 [PMID: 29228378]
  32. Neuropsychopharmacology. 2006 May;31(5):1075-84 [PMID: 16407905]
  33. Neuroimage. 2015 Nov 15;122:440-50 [PMID: 26277774]
  34. Sci Rep. 2018 Apr 12;8(1):5129 [PMID: 29651013]
  35. Psychopharmacology (Berl). 2002 May;161(3):324-30 [PMID: 12021836]

MeSH Term

Citalopram
Decision Making
Double-Blind Method
Gambling
Humans
Male
Risk-Taking
Serotonin
Uncertainty

Chemicals

Citalopram
Serotonin

Word Cloud

Created with Highcharts 10.0.0uncertaintysocialoutcomesbehaviorsdecisionsgambledifferentriskcitalopramgamblingnonsocialconditiondeterminedincreasedacceptancegamblesmanyinstanceslifedecisions'hingesomeoneelse'schoicesieBehavioralpharmacologicalworkpreviouslyfocusedtypesambiguitymuchtwostudiesusingdouble-blindplacebo-controlledwithin-subjectdesignadministratedselective-serotonin-reuptakeinhibitormaleparticipantsinvestigatedtaskanotherparticipantcointossobservedespeciallylowergainshigherlossesmightindicativepositivitybiasexpectationsconditionshighothers'similareffectfoundoverallbehaviorirrespectivesourcesocial/nonsocialresultsprovideinsightscognitiveneurochemicalprocessesunderlyingimplicationsresearchrisk-takinghealthyclinicalpopulationsInfluencesserotonin

Similar Articles

Cited By